{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:46:19Z","timestamp":1782470779206,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eprac.2026.03.089","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:46:03Z","timestamp":1774658763000},"page":"1124-1131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Between the Guidelines: Variability in Management of Patients With Cystic Fibrosis and Dysglycemia"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-8686","authenticated-orcid":false,"given":"Holly","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nellie","family":"Hani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Runchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie Larson","family":"Ode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Kaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.03.089_bib1","series-title":"2023 patient registry annual data report","year":"2024"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.089_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2337\/dc25-0044","article-title":"Trends in cystic fibrosis-related diabetes epidemiology between 2003 and 2018 from the U.S. Cystic Fibrosis Foundation Patient Registry","volume":"48","author":"Kohler","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.089_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.089_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF01957574","article-title":"Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis","volume":"151","author":"Lanng","year":"1992","journal-title":"Eur J Pediatr"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.089_bib5","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/ppul.25572","article-title":"Nutritional status between 5-10 years is associated with cystic fibrosis-related diabetes in adolescence","volume":"56","author":"Ararat","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2026.03.089_bib6","first-page":"S20","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.089_bib7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.089_bib8","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American diabetes association and a clinical practice guideline of the cystic fibrosis foundation, endorsed by the pediatric endocrine society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.089_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1399-5448.2009.00632.x","article-title":"Oral glucose tolerance testing in children with cystic fibrosis","volume":"11","author":"Ode","year":"2010","journal-title":"Pediatr Diabetes"},{"issue":"3 Pt 1","key":"10.1016\/j.eprac.2026.03.089_bib10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline","volume":"162","author":"Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.089_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","article-title":"Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline","volume":"17","author":"Chan","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.089_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108703","article-title":"Early glucose abnormalities revealed by continuous glucose monitoring associate with lung function decline in cystic fibrosis: a five-year prospective study","volume":"38","author":"Rakotoarisoa","year":"2024","journal-title":"J Diabetes Its Complications"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.089_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-5448.2008.00451.x","article-title":"One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements","volume":"10","author":"Mozzillo","year":"2009","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.089_bib14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jcf.2018.05.005","article-title":"Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes","volume":"17","author":"Frost","year":"2018","journal-title":"J Cystic Fibrosis"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.089_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2352-4642(25)00099-9","article-title":"Insulin for early glycaemic abnormality in children with cystic fibrosis without cystic fibrosis-related diabetes (CF-IDEA): a randomised controlled trial","volume":"9","author":"Hameed","year":"2025","journal-title":"The Lancet Child Adolesc Health"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.089_bib16","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1164\/rccm.202411-2312OC","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on glucose tolerance and abnormal glucose metabolism: a phase 3b, open-label clinical trial","volume":"211","author":"Durieu","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eprac.2026.03.089_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1623654","article-title":"Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic fibrosis-related diabetes: a systematic review","volume":"16","author":"Giordano","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2026.03.089_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1183288","article-title":"A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers","volume":"14","author":"Hicks","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.089_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcjd.2024.09.001","article-title":"Cystic fibrosis-related diabetes: a first Canadian clinical practice guideline","volume":"49","author":"Coriati","year":"2025","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.eprac.2026.03.089_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111589","article-title":"International diabetes Federation position statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes","volume":"209","author":"Bergman","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.089_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc10-1604","article-title":"Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis","volume":"34","author":"Brodsky","year":"2011","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.089_bib22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ppul.23237","article-title":"Elevation of one hour plasma glucose during oral glucose tolerance testing","volume":"50","author":"Sheikh","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.089_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2514787","article-title":"Time to replace the oral glucose tolerance test for cystic fibrosis related diabetes first-step screening? Establishing glycemic tools relevant to cystic fibrosis","volume":"57","author":"Estey","year":"2025","journal-title":"Ann Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.089_bib24","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab049","article-title":"Carbohydrate intake prior to oral glucose tolerance testing","volume":"5","author":"Klein","year":"2021","journal-title":"J Endocr Soc"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.089_bib25","first-page":"246","article-title":"Consensus report on nutrition for pediatric patients with cystic fibrosis","volume":"35","author":"Borowitz","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.089_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.03.089_bib27","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.089_bib28","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1210\/clinem\/dgab857","article-title":"Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis","volume":"107","author":"Scully","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.03.089_bib29","first-page":"3","article-title":"Cystic fibrosis-related diabetes: clinical approach and knowledge gaps","volume":"46","author":"Prentice","year":"2023","journal-title":"Paediatr Respir Rev"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.089_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcjd.2018.04.008","article-title":"Cystic fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels","volume":"43","author":"Gilmour","year":"2019","journal-title":"Can J Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.089_bib31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/medicina60030477","article-title":"The role of continuous glucose monitoring in detecting early dysglycemia and clinical outcomes in patients with cystic fibrosis","volume":"60","author":"Kirigin Bilo\u0161","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.089_bib32","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.2337\/dc19-1690","article-title":"Lessons from continuous glucose monitoring in youth with pre\u2013type 1 diabetes, obesity, and cystic fibrosis","volume":"43","author":"Chan","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.089_bib33","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1210\/clinem\/dgab692","article-title":"The relationship between continuous glucose monitoring and OGTT in youth and young adults with cystic fibrosis","volume":"107","author":"Chan","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.03.089_bib34","series-title":"Cystic fibrosis: Diagnosis and management","year":"2017"},{"key":"10.1016\/j.eprac.2026.03.089_bib35","series-title":"Management of cystic fibrosis diabetes","year":"2022"},{"key":"10.1016\/j.eprac.2026.03.089_bib36","article-title":"Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: a French survey from the 47 centers","volume":"28","author":"Weiss","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.089_bib37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.089_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/19322968221108424","article-title":"Determination of time in range associated with HbA1c \u22647% in a prospective cohort of patients with type 1 diabetes using continuous glucose monitoring for three months","volume":"18","author":"G\u00f3mez","year":"2024","journal-title":"J Diabetes Sci Technol"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.089_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71267","article-title":"Utility of continuous glucose monitors for improved detection of cystic fibrosis-related diabetes","volume":"60","author":"Moore","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.03.089_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1527932","article-title":"Glucose >200 mg\/dL during continuous glucose monitoring identifies adult patients at risk for development of cystic fibrosis related diabetes","volume":"2016","author":"Taylor-Cousar","year":"2016","journal-title":"J Diabetes Res"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.089_bib41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2213-8587(17)30400-X","article-title":"Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial","volume":"6","author":"Ballmann","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.089_bib42","first-page":"CD004730","article-title":"Drug treatments for managing cystic fibrosis-related diabetes","volume":"10","author":"Onady","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.089_bib43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jcjd.2023.02.002","article-title":"Canadian cystic fibrosis\u2013related diabetes clinical practice survey: analysis of current practices and gaps in clinical care","volume":"47","author":"Potter","year":"2023","journal-title":"Can J Diabetes"},{"issue":"11","key":"10.1016\/j.eprac.2026.03.089_bib44","doi-asserted-by":"crossref","first-page":"e4786","DOI":"10.1210\/clinem\/dgab442","article-title":"Potential role for the use of gliptins in cystic fibrosis-related diabetes","volume":"106","author":"Ismail","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.089_bib45","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.03.089_bib46","article-title":"Cystic fibrosis-related diabetes: the patient perspective","volume":"26","author":"Mason","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.03.089_bib47","article-title":"Coronary artery disease in patients with cystic fibrosis \u2013 a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2026.03.089_bib48","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1258\/jrsm.2010.s11010","article-title":"Ischaemic heart disease \u2013 a new issue in cystic fibrosis?","volume":"103","author":"Perrin","year":"2010","journal-title":"J R Soc Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:49:10Z","timestamp":1782467350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26009122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1530891X26009122"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.089","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Between the Guidelines: Variability in Management of Patients With Cystic Fibrosis and Dysglycemia","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}